ReCode Therapeutics utilizes its Selective Organ Targeting (SORT) lipid nanoparticle platform to deliver mRNA and gene correction therapies directly to specific organs and tissues, bypassing the liver. The company focuses on developing treatments for genetically defined diseases, such as primary ciliary dyskinesia and cystic fibrosis, where no effective therapies currently exist.
Funding
$357M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFFounders
Product
Problem
Many genetic medicines face delivery challenges, particularly in reaching target organs and tissues beyond the liver, limiting their therapeutic potential for a wide range of genetically defined diseases. Current delivery systems often lack the precision needed to effectively target specific cells and tissues, hindering the development of treatments for conditions like primary ciliary dyskinesia and cystic fibrosis.
Solution
ReCode Therapeutics is developing a Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform designed to deliver mRNA and gene correction therapies directly to specific organs and tissues, bypassing the liver. This modular technology enables targeted delivery of genetic medicines, optimizing therapeutic efficacy and minimizing off-target effects. The SORT LNP platform facilitates the packaging and delivery of a range of genetic medicines through multiple routes of administration, offering versatility in addressing various disease targets. ReCode's approach aims to overcome the limitations of existing genetic medicine delivery systems, enabling the development of disease-modifying therapeutics for rare diseases.
Target Audience
The primary target audience includes individuals with genetically defined diseases, such as primary ciliary dyskinesia and cystic fibrosis, who currently lack effective treatment options.
Features
- SORT LNP platform for targeted delivery of genetic medicines to organs and tissues beyond the liver
- Modular technology enabling the packaging and delivery of a wide range of genetic medicines
- Optimized mRNA and gene correction capabilities with redosing potential
- Multiple routes of administration for versatile therapeutic application